Dendreon Corp.
3005 First Avenue
Seattle,
WA 98121
Phone: 206-256-4545
Fax: 206-256-0571
Web Site: http://www.dendreon.com
| Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics that harness the immune system to fight cancer. Its product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. The company's product candidates include Provenge (sipuleucel-T), an active cellular immunotherapy that is in FDA priority review status for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), which has completed phase 1 clinical trials for the treatment of breast, ovarian, and colon cancers. Dendreon also has various products in preclinical studies, which include Trp-p8 for the treatment of lung, breast, prostate, and colon cancers; CEA for the treatment of breast, lung, and colon cancers; CA-9 (MN) for the treatment of kidney, colon, and cervical cancers; and Anti-Serine Protease for the treatment of multiple cancers. The company has collaborative agreements with Genentech, Inc. for the preclinical research, clinical development, and commercialization of products derived from trp-p8, an ion channel found in prostate cancer cells; and with Amgen Fremont, Inc. for the discovery, development, and commercialization of human monoclonal antibodies against a membrane-bound serine protease. Dendreon, formerly known as Activated Cell Therapy, Inc., was founded in 1992. The company is based in Seattle, Washington. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Dr. Mitchell H. Gold M.D., 40
Chief Exec. Officer, Pres
|
N/A
|
N/A |
Mr. Gregory T. Schiffman MBA, CPA, 49
Chief Financial Officer, Sr. VP and Treasurer
|
$
15.00K |
N/A |
Dr. David L. Urdal Ph.D., 58
Chief Scientific Officer, Sr. VP
|
N/A
|
N/A |
Mr. Richard F. Hamm Jr., 48
Sr. VP of Corp. Devel., Sec. and Gen. Counsel
|
N/A
|
N/A |
Dr. Mark Frohlich M.D., 46
Chief Medical Officer and Sr. VP of Clinical Affairs
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-06
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
Profile
